Revenues, Recognition and Allowances (Tables)

9 Months Ended

Sep. 30, 2019

Revenue from Contract with Customer [Abstract]

Disaggregation of Revenues

Net revenues for the three and nine months ended September 30, 2019 and 2018 were as follows:

	Three months ended September 30,				Nine months ended September 30,
	2019		2018		2019		2018
Company product sales	$	18,228	$	16,375	$	48,591	$	44,288
Contract manufacturing sales	167		1,878		1,097		4,626
Research and development services and other income	71		41		$	241	$	174
Revenue, net	$	18,466	$	18,294	$	49,929	$	49,088

Disaggregated information for the Company product sales revenue has been recognized in the accompanying unaudited interim Condensed Consolidated Statements of Operations, and is presented below according to contract type:

	Three months ended September 30,				Nine months ended September 30,
Company Product Sales	2019		2018		2019		2018
Topical	$	13,271	$	10,503	$	35,240	$	26,297
Injectables	4,957		5,872		13,351		17,991
Total	$	18,228	$	16,375	$	48,591	$	44,288

Schedule of Accounts, Notes, Loans and Financing Receivable

The Company's adjustments for the deductions to gross product sales are as follows:

	Three months ended September 30,				Nine months ended September 30,
	2019		2018		2019		2018
Gross product sales	$	41,814	$	40,111	$	108,550	$	124,801
Deduction to gross product sales:
Chargebacks and billbacks	14,573		10,739		37,285		49,103
Wholesaler fees for service	2,355		1,662		6,303		2,774
Sales discounts and other allowances	6,658		11,335		16,371		28,636
Total reduction to gross product sales	$	23,586	$	23,736	$	59,959	$	80,513
Company product sales, net	$	18,228	$	16,375	$	48,591	$	44,288